香港, 2026年3月31日 - (亚太商讯 via SeaPRwire.com) - 山东极视角科技股份有限公司（以下简称"极视角"）即将于3月30日登陆香港联合交易所主板，冲击"视觉语言大模型第一股"。这家成立于2015年的AI视觉公司，用十年时间从深圳起步，扎根山东青岛，成长为国家级专精特新"小巨人"与福布斯中国"独角兽"。截至2025年9月30日，公司累计交付项目超过6,000个，产品复购率超过80%，客户覆盖逾100个行业，并于2024年成功实现盈利，成为国内少数实现盈利的AI视觉企业之一。在这份成绩单背后，是一条与众不同的商业化路径。而这条路径的起点，要从三位"90后"创始人的创业初心说起。三位"90后"的产业初心：让AI不再"悬浮"极视角的创始人陈振杰，1992年出生于澳门，在北大求学期间便对商业与技术的结合产生浓厚兴趣。凭借敏锐的商业洞察力，加之联合创始人罗韵在香港科技大学攻读人工智能博士的学术研究领域的专长，2015年，他们共同创立极视角，立志将AI技术转化为真正改变产业的生产力。十年间，陈振杰带领团队从深圳起步，将总部迁至产业基础雄厚的山东青岛，一步一个脚印深耕B端市场。他本人先后入选《福布斯》"亚洲30位30岁以下精英榜"和胡润U30中国创业领袖榜，并成为国家科技创业领军人才。极视角的现任执行董事兼副总经理陈硕曾公开表示："我们读硕士和博士期间，就预感到人工智能将会应用于千行百业，场景也会呈现多样化与碎片化，只靠一家企业无法满足所有需求。于是我们开创了‘算法商城’模式。"正是这一模式，奠定了极视角与众不同的商业化路径。破解"碎片化"难题：构建独特"自研+生态"模式正是早期对产业一线的深入观察，让陈振杰敏锐地捕捉到B端市场的核心痛点。他曾提到，"B端市场最大的痛点正是‘碎片化’。"不同行业、不同企业、甚至同一企业的不同生产环节，对AI的需求千差万别。如果每个场景都需要从零开始开发算法，成本高昂，周期漫长，根本无法规模化。面对碎片化的市场需求，极视角的应对策略是将AI解决方案的开发过程"拆解"和"重构"。公司自主研发了AI视觉语言模型作为底层能力，同时打造算法开发平台"极市"和交付平台"极星""极栈"，通过平台化、工具化的方式，大幅降低算法开发的成本和门槛。具体而言，极市专注于计算机视觉算法，为开发者提供全面的基础设施支持，包括在线编程工具、大模型API、训练任务管理、自动测试及多种芯片的硬件兼容性，可显著提升算法开发效率。通过利用真实世界场景数据，极市平台训练的算法也可实现高识别准确率。基于这套自主研发的全栈式技术平台，极视角构建起独特的"自研+生态"模式。截至2025年9月30日，公司的AI计算机视觉算法商城已展示逾1,500种算法，涵盖逾100个行业。更重要的是，公司建立了由数十万AI算法开发者组成的全球社区，累计服务客户超过3,000名，自成立以来已交付逾6,000个项目。算法保持90%以上的准确率，并可灵活组合、定制，满足不同客户的个性化需求。此外，在自主研发的全栈式工具链及可扩展的开发者生态系统的支持下，公司将项目交付周期缩短至仅需八至十周，远快于行业平均水平。盈利能力强劲：收入、利润、毛利率持续向好商业模式的可行性，最终体现在财务数据上。公司收入由2022年的1.016亿元增长至2024年的2.573亿元，复合年增长率达59.2%；毛利率由2022年的30.6%提升至2024年的40.2%；2024年录得年内利润871万元。截至2025年9月30日止九个月，公司实现收入1.363亿元，同比增长71.7%，毛利率进一步提升至44.9%。凭借先进的技术积淀与全栈式AI基础设施，极视角已在计算机视觉解决方案及大模型解决方案领域确立稳固地位。根据弗若斯特沙利文的数据，按销售收入计，公司2024年在中国新兴企业级计算机视觉解决方案市场以软件为中心的提供商中排名第三，占有1.6%的市场份额。公司还凭借技术实力入选工信部人工智能揭榜挂帅任务，进一步验证了其在行业中的创新能力。展望未来，AI技术在B端市场的渗透空间仍然广阔。根据弗若斯特沙利文的数据，中国企业级计算机视觉解决方案市场规模预计将从2024年的111亿元增长至2029年的970亿元，年复合增长率高达54.3%。公司表示，未来将持续加大研发投入，不断迭代AI视觉语言模型及核心平台能力，在开发、训练与部署AI计算机视觉及大模型解决方案方面，保持行业领先地位。从三位"90后"的创业初心，到千行百业的AI落地，极视角正以稳健的耐力与清晰的路径，在AI商业化的长跑中行稳致远。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 31, 2026 - (ACN Newswire via SeaPRwire.com) - Bringing artificial intelligence from the laboratory to a broad spectrum of industries—particularly in the B2B market—demands that AI companies overcome a formidable set of challenges: how to precisely match complex, ever-evolving business scenarios; how to achieve scalable delivery; and how to establish a sustainable business model.Extreme Vision, based in Qingdao, Shandong, has delivered its answer through a compelling set of metrics. As of September 30, 2025, the Company had completed over 6,000 projects, recorded a product repurchase rate exceeding 80%, and served more than 100 industries, including manufacturing, energy, retail, and transportation. Revenue grew from RMB101.6 million in 2022 to RMB257.3 million in 2024, representing a compound annual growth rate of 59.2%. The Company turned profitable in 2024.A Platform-based Approach to Tackling the Fragmentation ChallengeExtreme Vision was founded by three entrepreneurs born in the 1990s: Mr. Chan Chan Kit, Ms. Luo Yun, and Mr. Chen Shuo. Mr. Chan Chan Kit holds a direct stake of 16.05% in the Company and serves as its largest shareholder, legal representative, chairman of the board, executive director, and general manager. The three founders, all alumni of Sun Yat-sen University, first conceived the idea of starting a business during their undergraduate studies.“The biggest challenge in the B2B market is fragmentation,” Mr. Chan once noted. Different industries, different enterprises, and even different production processes within the same company all have vastly different AI requirements. If each scenario requires developing algorithms from scratch, the cost is prohibitive, the timeline is protracted, and scaling becomes virtually impossible. This is precisely the “B2B chasm” that many AI companies struggle to cross. Based on this insight, Extreme Vision pioneered the AI Vision Algorithm Marketplace.As of September 30, 2025, Extreme Vision’s algorithm marketplace has launched 1,517 algorithms, including 1,369 algorithms co-developed with third-party developers. Covering application scenarios in over 100 industries, the platform has served more than 3,000 customers and delivered over 6,000 projects since its establishment. Notably, the product repurchase rate has exceeded 80%, reflecting the strong standardization of its solutions and robust market recognition.Self-developed AI infrastructure empowers efficient implementation. The Company’s self-developed AI infrastructure enables efficient algorithm development and rapid solution development. On the one hand, leveraging its self-developed full-stack technology platform, Extreme Vision has built an industry-leading AI infrastructure that covers the entire lifecycle, including data annotation, model training, algorithm development, algorithm testing and inference deployment. On the other hand, the integrated tool engines within its AI development infrastructure significantly lowering the barriers to algorithm development and drastically reducing the time required for customized algorithm development.Multi-industry Implementation: Project Practice as a Driver for Healthy GrowthLeveraging its platform-based capabilities, Extreme Vision has applied its technology to real-world business scenarios across various sectors, delivering actionable and reusable solutions.In terms of industrial manufacturing, Extreme Vision deployed an EHS+AI intelligent monitoring system for CR Beer. By implementing 25 categories of risk-identification algorithms, the system accurately captures risk scenarios such as the improper wearing of safety ropes and goggles, hoisting operations, and unauthorized personnel intrusion during equipment operation. This has successfully transformed traditional passive safety management into proactive, real-time, and automated risk control.In terms of environmental and energy sectors, Extreme Vision has built an intelligent security management platform, “Halo Guard” for China Everbright Environmental Energy. Equipped with nearly 30 AI vision algorithms for safety management and control, the platform conducts real-time monitoring of high-risk operational scenarios such as unloading platforms and burning zones, significantly enhancing operational safety.In the higher education sector, Extreme Vision has jointly established the “Artificial Intelligence Comprehensive Practice Center” with the School of Smart City at Beijing Union University. Leveraging its Extreme Flow platform, the Company supports algorithm teaching and research in universities, helping to cultivate AI talent.In the transportation and mobility sector, Extreme Vision has identified new application scenarios for large model solutions. Using large model technologies, the Company has generated autonomous driving simulation scenario data and conducted hallucination detection for a leading automotive retailer, helping the client reduce reliance on real-world road data collection and optimize the R&D process.These projects not only demonstrate the breadth and depth of Extreme Vision's technology implementation but also collectively underpin the Company's sustained growth. Each successfully delivered project generates experience and reusable modules for future projects, creating a virtuous cycle that contributes to a product repurchase rate of over 80%.Profitability Continuously Validated, Large Model Emerges as a New Growth DriverAs its commercial value continues to be validated, Extreme Vision's profitability has also shown strong growth momentum. The Company's revenue grew from RMB101.6 million in 2022 to RMB257.3 million in 2024, representing a compound annual growth rate (CAGR) of 59.2%. The gross profit margin improved from 30.6% in 2022 to 40.2% in 2024. The Company recorded a profit of RMB8.71 million in 2024, making it one of the few profitable AI vision companies in China. For the nine months ended September 30, 2025, the Company achieved revenue of RMB136.3 million, a year-on-year increase of 71.7%, with the gross profit margin further rising to 44.9%.Notably, the large model solutions launched by the Company in 2024 contributed RMB62.12 million in revenue, accounting for 24.1% of total revenue. This has become a new growth driver and is expected to unlock further market opportunities.In terms of R&D investment, the Company continued to increase its efforts. R&D expenditure reached RMB44.82 million in 2024, an increase of 22.6% compared to 2023. As of September 30, 2025, the Company had a professional team of 101 R&D personnel. According to the Prospectus, the Company intends to use approximately 60.0% of the net proceeds from the IPO (HK$260.6 million) to enhance R&D capabilities, including the construction of large models and AI infrastructure, as well as the upgrade of AI-PaaS middleware.Broad Market Prospects: The Platform Flywheel AcceleratesIndustry prospects are promising. According to Frost & Sullivan, the market size of China’s emerging enterprise-level computer vision solutions is projected to grow from RMB11.1 billion in 2024 to RMB97.0 billion in 2029, representing a CAGR of 54.3%. This represents an almost eightfold increase in market size over the next five years, indicating strong inherent growth potential in the sector.As large models gain traction globally, market expectations for AI have been further elevated. However, in the B2B market, no matter how cutting-edge the technology is, it must ultimately return to the simple logic of “usability, practicality, and cost controllability.” Extreme Vision's experience shows that a competitive edge for AI companies lies not only in technological leadership but also in the ability to develop standardized solutions for complex industrial scenarios and scale them through platforms and ecosystems.From algorithms to applications, from project delivery to customer retention, Extreme Vision has remained committed to its mission of pushing technological boundaries and harnessing technology for good—building an AI flywheel that continuously generates commercial value. As AI technology permeates all industries, from industrial safety and energy inspection to retail operations, the demand for fragmented long-tail scenarios continues to emerge, positioning Extreme Vision for accelerated growth. However, whether it can continuously increase market share and improve cash flow amid fierce competition remains a core challenge post-listing. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月31日 - (亚太商讯 via SeaPRwire.com) - 西藏智汇矿业股份有限公司（股票代码：2546.HK，"智汇矿业"或"本公司"）今日公布截至2025年12月31日止年度的经审核全年业绩。公告显示，受惠于有色金属价格上行及产能释放，公司全年实现营收约人民币6.16亿元，同比增长104.4%；归母净利润达人民币1.50亿元，同比激增168.3%。 尤为值得关注的是，公司盈利能力显著增强，毛利率从去年同期的34.7%进一步优化提升至36.4%。此外，董事会提议派发末期股息每股人民币0.102元，分红比例约占核心利润的30%，彰显了公司对股东长期支持的回馈诚意及对未来发展的信心。 毛利率显著优化，高效运营与规模效应释放盈利弹性2025年，智汇矿业在良好的市场环境下，通过精细化管理实现了成本与收入的良性剪刀差。数据显示，公司全年销售成本同比增长99.0%，低于收入增速（104.4%）5.4个百分点，这一结构性优化直接推动了毛利润以114.4%的幅度增长，毛利率提升至36.4%。 这一成绩的取得，不仅得益于入选矿石品位的自然提升（铅+锌合计6.73%）及规模效应带来的单位成本摊薄，更源于公司对生产全流程的高效管控。在产量翻倍的背景下，公司依然保持了卓越的成本控制能力，实现了利润增速远超营收增速的高质量发展。 12号矿床产能释放，奠定增长基石业绩爆发的核心驱动力来自核心资产的全面投产。报告期内，公司12号矿床（Pb12）地下矿山建设项目如期完工，并于2025年6月正式通过安检验收投入生产。 这一里程碑式的进展，不仅为公司提供了新的高质量矿石来源，更极大地延长了矿山的服务年限。叠加露天矿山恢复正常作业，公司铅、锌、铜精矿销量分别实现了160%、76%和311%的大幅增长，为业绩翻倍奠定了坚实的产能基础。 坚持高分红政策，践行股东回报承诺智汇矿业始终将股东回报视为企业发展的核心责任。随着2025年12月公司在港交所主板成功上市，资本实力显著增强的同时，公司亦确立了持续、稳定的分红政策。 基于优异的业绩表现，董事会建议派发末期股息每股人民币0.102元。以此计算，年度分红金额占归母净利润比例约30%。这一高分红举措充分体现了管理层对现金流生成能力的信心，以及践行对投资人回报承诺的坚定决心。 展望未来智汇矿业管理层表示："2025年是智汇矿业发展历程中具有里程碑意义的一年。我们不仅完成了上市愿景，更通过技术升级和管理优化，实现了‘收入增长快于成本增长’的高质量发展模式。未来，我们将继续深耕西藏资源优势，加大勘探投入，并寻求优质的并购机会，致力于成为领先的有色金属矿业公司，为股东创造长期可持续的价值。" Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月31日 - (亚太商讯 via SeaPRwire.com) - 日前，2026年两会政府工作报告明确提出打造生物医药等新兴支柱产业，中国创新医药行业正迎来政策春风。在此背景下，康希诺生物（06185.HK/688185.SH）发布的2025年业绩公告，清晰地展现了这家创新疫苗代表企业如何凭借清晰的商业逻辑与全球视野穿越周期，步入价值兑现的新阶段。业绩扭亏为盈，产品矩阵释放增长动能根据2025年年度业绩公告，公司全年实现营业收入约10.68亿元，同比增长26.18%；归属于母公司所有者的净利润约为2787.27万元，成功实现扭亏为盈。这一数据不仅标志着公司走出了研发投入与市场波动的低谷，更验证了其依靠常规疫苗商业化构建了稳定的"自我造血"能力。本次扭亏为盈的核心驱动力并非短期因素，而是源于主营业务的内生增长。公告显示，公司核心产品四价流脑结合疫苗曼海欣(R)收入持续增长，同时13价肺炎结合疫苗优佩欣(R)快速铺开，形成了稳定的现金流模式。这种收入结构的优化，提升了盈利质量的可持续性，为市场提供了更确定的估值锚点。此外，公司在报告期内获得了多项政府专项补助及国际专项研发资金支持，这也体现了国家层面对康希诺生物技术实力与创新价值的高度认可。核心产品放量在即，管线储备夯实成长根基康希诺生物的价值不止于短期盈利，而是由层次分明、梯次配备的产品管线所支撑，这也为其后续的业绩确定性提供了坚实支撑。作为康希诺生物的核心增长引擎，中国首个获批的四价流脑结合疫苗曼海欣(R)的潜力正在全面释放。2026年2月，该产品扩大适用人群的补充申请成功获批，接种范围扩展至3月龄至6周岁的婴幼儿及儿童。本次曼海欣(R)扩龄至6岁，为即将进入校园生活的学龄儿童提供了新选择，也为产品扩展了可观的市场空间。另一核心产品优佩欣(R)则展现出强大的协同效应。其为国内首款采用CRM197和破伤风类毒素（TT）双载体的13价肺炎球菌多糖结合疫苗（PCV13i），于2025年6月获批上市，同年9月起发往全国并陆续启动接种。在商业化路径上，优佩欣(R)与曼海欣(R)的协同效应将显著降低边际销售成本，提升整体商业化效率。此外，中期储备同样扎实，公司的婴幼儿组分百白破疫苗DTcP（以下简称"婴幼儿用DTcP"）已被纳入优先审评程序，有望加快上市进程。截至目前，暂无国内疫苗厂商研发的组分百白破疫苗获批上市，康希诺生物婴幼儿用DTcP将每种百日咳抗原进行单独纯化，以确定的比例配制，从而可以确保产品质量的批间一致性，使产品的质量更加稳定。此外，婴幼儿用DTcP的开发，也是青少年及成人用组分百白破疫苗和以组分百白破为基础的联合疫苗进一步研发的基础。组分百白破疫苗产品组合将进一步丰富公司产品策略，提升公司核心竞争力。而长期想象力的天花板，则由研发管线持续抬升。从近期兑现到中期储备再到长期探索，康希诺生物的价值绝不局限于现有产品。研发投入位居前列，技术平台构筑护城河作为创新疫苗领军企业，康希诺生物始终坚持"长期主义"的投入策略，确保了公司保持前沿技术探索，为其长期竞争力奠定了坚实基础。目前，康希诺生物拥有一支全球顶尖的团队，创始人及核心技术人员在生物制药行业平均拥有超过25年的经验，均曾就任于研发、生产及商业化国际重磅疫苗的全球制药或生物科技公司的重要岗位。这支团队不仅带来了全球视野下的管线布局思路，更将国际标准的研发管理体系深度融入日常运营，持续完善从实验室研发到商业落地的全链条闭环。此外，依托多年技术积累，公司已形成病毒载体疫苗、合成疫苗、蛋白结构设计与VLP组装、mRNA疫苗以及制剂与给药技术五大核心技术平台，构建多技术路线协同发展的创新体系，为全生命周期疫苗产品研发奠定坚实技术基。公司坚持差异化、创新化发展道路，聚焦多联多价疫苗、新型给药技术，依托五大核心技术平台研发全球首创或同类最优的疫苗品种。正是得益于技术平台的强力支撑，公司得以持续推出曼海欣(R)、优佩欣(R)等具有代际优势的创新产品，并在行业保持领先地位。国际认证再获突破，全球布局步入快车道与此同时，在国内疫苗市场竞争日趋激烈的背景下，康希诺生物的国际化布局正加速推进。日前，公司公告其生产基地已通过马来西亚药监局（简称"NPRA"）PIC/S GMP认证。PIC/S是国际药品检查、认证的权威机构，由数十个国家的药品监管机构组成。通过此项认证，不仅意味着曼海欣(R)和优佩欣(R)的生产质量体系达到国际领先水平，也为产品进入更多国际市场创造有利条件。事实上，康希诺生物的国际化布局早已开始。曼海欣(R)自2024年以来已获得印度尼西亚注册证书并通过Halal认证，优佩欣(R)也正加快国际化布局步伐。目前，公司已与海外多家合作方签署战略合作协议，加强产品的本地化合作，包括商业化、联合研发与临床研究以及本地化生产等方面。可见，康希诺生物通过"技术转移+本地化生产"的策略，已从单纯的产品出口转向技术输出，建立起一道差异化的国际市场护城河。价值低估待重估，戴维斯双击有望开启综合来看，康希诺生物正以愈发清晰的商业逻辑证明其已穿越周期。然而，当前市值并未充分反映其投资价值。一方面，核心产品曼海欣(R)扩龄、优佩欣(R)放量以及已被纳入优先审评程序的婴幼儿用DTcP，加之国际化订单落地与海外市场的开拓，构成了未来明确的业绩增长点；另一方面，生物医药作为"新兴支柱产业"的定位，将提升整个板块的估值中枢。随着业绩持续兑现，市场认知差将逐步修复，公司有望迎来业绩与估值同步提升的"戴维斯双击"。在生物医药成为国家新兴支柱产业的时代背景下，康希诺生物的长期投资价值，值得市场予以更高的关注与期待。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 31, 2026 - (ACN Newswire via SeaPRwire.com) - China's 2026 Report on the Work of the Government identified biopharmaceuticals as an emerging pillar industry, underscoring a supportive policy environment for innovative drugmakers. In this context, CanSino Biologics Inc. (688185.SH/06185.HK) has released its Annual Results For The Year 2025, marking a return to profitability and highlighting steady progress in its commercialization efforts.Return to Profitability Driven by Vaccine Portfolio GrowthAccording to its annual results, CanSinoBIO achieved total revenue of approximately RMB 1.068 billion, representing a year-on-year increase of 26.18%. Net profit attributable to shareholders reached RMB 27.9 million, marking a return to profitability.The turnaround reflects more than a cyclical rebound and suggests the company is building a more sustainable revenue base through the commercialization of routine vaccines. This has strengthened its ability to generate consistent cash flow.The improvement was driven primarily by organic growth in core operations rather than one-off factors. During the reporting period, the Company’s Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (trade name: Menhycia(R)) maintained steady revenue growth, while its 13-valent Pneumococcal Conjugate Vaccine (trade name: iPneucia(R)) gained market traction following its launch. A more balanced revenue mix has improved earnings visibility.In addition, CanSinoBIO received multiple government grants and international R&D funding support during the year, reflecting recognition of its technological capabilities and innovative value.Core Products Set to Scale Up, Pipeline Supports Future GrowthBeyond near-term earnings, the company is supported by a diversified pipeline that provides both mid- and long-term growth drivers.As a core growth driver for CanSinoBIO, Menhycia(R), China’s first domestically developed quadrivalent meningococcal conjugate vaccine, continues to expand its market reach. In February 2026, the company announced that the supplemental application to expand the age range of applicable population of Menhycia(R) from “children aged from 3 months to 3 years old (47 months)” to “children aged from 3 months to 6 years old (83 months)” has been approved, further broadening its target population.Meanwhile, iPneucia(R)—China’s first 13-valent pneumococcal conjugate vaccine using a dual-carrier system (CRM197 and tetanus toxoid)—is expected to generate commercial synergies with Menhycia(R). Shared distribution and marketing channels could help lower marginal sales costs and improve overall efficiency.In addition, the company’s mid-term pipeline remains robust. It’s absorbed diphtheria, tetanus, and acellular pertussis (components) combined vaccine (the “DTcP”) for infants (below 2 years old) (the “DTcP Infant”)has been included in the priority review pathway, which will accelerate its approval timeline.To date, no component-based DTaP vaccine developed by domestic manufacturers has been approved for market launch in China. The infant DTcP vaccine is formulated with individually purified pertussis antigens in defined ratios to ensure consistent quality and stability. Its development also lays the groundwork for adolescent and adult component Tdap vaccines and combination vaccines, enhancing the Company’s product portfolio and core competitiveness.From near-term delivery to mid-term development and long-term innovation, CanSino Biologics’ value goes beyond its existing productsR&D Capabilities Support Long-Term CompetitivenessAs a leading innovative vaccine company, CanSinoBIO consistently adheres to a long-term strategy, ensuring the company remains at the forefront of technological exploration and laying a solid foundation for its sustained competitiveness.Its core talent team brings an average of more than 25 years of industry experience across global pharmaceutical and biotechnology companies, spanning research, manufacturing and commercialization. This has enabled the company to establish an integrated development system aligned with international standards and covering the full development cycle from early-stage research to commercialization.Over time, CanSinoBIO has also built five core technology platforms, including viral vector vaccines, synthetic vaccines, protein structure design and Virus-Like Particle (VLP) assembly, mRNA vaccines, and formulation and delivery technologies. These platforms support a diversified innovation system and provide a solid foundation for lifecycle vaccine development.The company continues to focus on differentiated innovation, including multivalent combination vaccines and novel delivery technologies, with the aim of developing globally competitive vaccine products.These technological capabilities have supported the launch of products like Menhycia(R) and iPneucia(R), reinforcing the company’s position in the vaccine sector.International Expansion Gains MomentumMeanwhile, amid intensifying competition in the domestic vaccine market, CanSinoBIO is accelerating its international expansion.Recently, the company announced that its manufacturing facility has passed the PIC/S GMP certification issued by Malaysia’s National Pharmaceutical Regulatory Agency (NPRA). PIC/S is an internationally recognized framework for pharmaceutical inspection and certification, comprising regulatory agencies from over 50 countries. This certification not only confirms that Menhycia(R) and iPneucia(R) meet international-quality standards but also enhances the company’s prospects for entering additional global markets.In fact, the Company’s international presence is well established, with Menhycia(R) obtaining Indonesian registration and Halal certification since 2024.The company has also entered into multiple strategic partnerships abroad, covering commercialization, joint R&D, clinical trials, and localized production. Through a “technology transfer + local manufacturing” approach, CanSinoBIO is expanding its presence beyond product exports toward broader technology-based collaboration.Growth Catalysts Point to Potential Re-RatingOverall, the latest results suggest CanSinoBIO is moving through an inflection point, supported by clearer commercialization pathways.Yet, its current market valuation may not fully reflect its investment potential. Looking ahead, potential growth drivers include the expanded indication for Menhycia(R), continued ramp-up in iPneucia(R) sales, the infant DTcP vaccine currently under priority review, as well as further international market expansion. At the same time, China’s policy support for biopharmaceuticals as a strategic sector could provide a favorable backdrop for valuation.As earnings continue to improve and market expectations adjust, the company may see both earnings growth and a re-rating in valuation multiples. Against the backdrop of China’s rising focus on biopharmaceutical innovation, CanSinoBIO’s long-term investment case is increasingly difficult to ignore. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com